Compare SMBC & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SMBC | DBVT |
|---|---|---|
| Founded | 1887 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.1M | 508.8M |
| IPO Year | N/A | N/A |
| Metric | SMBC | DBVT |
|---|---|---|
| Price | $60.35 | $19.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $63.63 | $31.75 |
| AVG Volume (30 Days) | 52.1K | ★ 763.5K |
| Earning Date | 01-26-2026 | 10-28-2025 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 25.22 | N/A |
| EPS | ★ 5.46 | N/A |
| Revenue | ★ $178,892,000.00 | $5,502,000.00 |
| Revenue This Year | $17.66 | $1,768.71 |
| Revenue Next Year | $4.13 | $1,028.88 |
| P/E Ratio | $11.05 | ★ N/A |
| Revenue Growth | ★ 10.39 | N/A |
| 52 Week Low | $45.10 | $2.93 |
| 52 Week High | $63.54 | $26.19 |
| Indicator | SMBC | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 56.61 |
| Support Level | $61.12 | $18.46 |
| Resistance Level | $63.54 | $22.89 |
| Average True Range (ATR) | 1.30 | 1.82 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 43.59 | 41.17 |
Southern Missouri Bancorp Inc is a USA-based holding company for Southern Missouri Savings Bank. The principal business of the bank consists of attracting retail deposits from the general public and using such deposits along with wholesale funding from the Federal Home Loan Bank of Des Moines, and to a lesser extent, brokered deposits, to invest in one- to four-family residential mortgage loans, mortgage loans secured by commercial real estate, commercial non-mortgage business loans, and consumer loans. It is engaged in providing the range of banking and financial services to individuals and corporate customers in its market areas. The company derives revenue principally from interest earned on loans, debt securities, bank card interchange fees, loan late charges and another fee income.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.